東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Formulations thermosensibles a base ...

Ruel-Gariepy, Eve.

FindBook

Google Book

Amazon

博客來

Formulations thermosensibles a base de chitosan pour la liberation prolongee de medicaments (French and English text).

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Formulations thermosensibles a base de chitosan pour la liberation prolongee de medicaments (French and English text)./
作者:	Ruel-Gariepy, Eve.
面頁冊數:	248 p.
附註:	Source: Dissertation Abstracts International, Volume: 66-04, Section: B, page: 2003.
Contained By:	Dissertation Abstracts International66-04B.
標題:	Health Sciences, Pharmacy. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=NR01147
ISBN:	9780494011478

Formulations thermosensibles a base de chitosan pour la liberation prolongee de medicaments (French and English text).
Ruel-Gariepy, Eve.

Formulations thermosensibles a base de chitosan pour la liberation prolongee de medicaments (French and English text). - 248 p.

Source: Dissertation Abstracts International, Volume: 66-04, Section: B, page: 2003.

Thesis (Ph.D.)--Universite de Montreal (Canada), 2005.

Thermosensitive pharmaceutical formulations are delivery systems that are liquid at room temperature and turn solid at 37°C. They can be administered through a needle in the intra-muscular or subcutaneous space and form an implant in situ. These formulations are currently studied as sustained release dosage forms. Recently, a chitosan-based hydrogel was developed. The main goal of the project was to characterize this new thermosensitive system and evaluate its potential as a sustained drug delivery vehicle.

ISBN: 9780494011478Subjects--Topical Terms:

1017737
Health Sciences, Pharmacy.

Formulations thermosensibles a base de chitosan pour la liberation prolongee de medicaments (French and English text).
LDR:03414nmm 2200301 4500 001 1827302
005 20061222092042.5
008 130610s2005 d
020 $a 9780494011478
035 $a (UnM)AAINR01147
035 $a AAINR01147
040 $a UnM $c UnM
100 1 $a Ruel-Gariepy, Eve. $3 1916234
245 1 0 $a Formulations thermosensibles a base de chitosan pour la liberation prolongee de medicaments (French and English text).
300 $a 248 p.
500 $a Source: Dissertation Abstracts International, Volume: 66-04, Section: B, page: 2003.
502 $a Thesis (Ph.D.)--Universite de Montreal (Canada), 2005.
520 $a Thermosensitive pharmaceutical formulations are delivery systems that are liquid at room temperature and turn solid at 37°C. They can be administered through a needle in the intra-muscular or subcutaneous space and form an implant in situ. These formulations are currently studied as sustained release dosage forms. Recently, a chitosan-based hydrogel was developed. The main goal of the project was to characterize this new thermosensitive system and evaluate its potential as a sustained drug delivery vehicle.
520 $a The characterization studies showed that the gelation kinetics at 37°C and the stability of the solutions varied according to the deacetylation degree of the chitosan used whereas gel erosion was not affected by this property. These studies also revealed that the solutions (before gelation) could be kept at least 2 months at room temperature or at 4°C. In vitro , hydrophilic macromolecules were released from the gel over a period of a few days. However, the gel could not sustain the release of low molecular weight hydrophilic compounds for more than 24 hours, under similar conditions.
520 $a In order to obtain a sustained release with low molecular weight hydrophilic compounds, they were encapsulated into liposomes before being incorporated in the thermosensitive solution. The addition of liposomes only slightly influenced the gelation kinetics of the thermosensitive solution at 37°C. Nevertheless, encapsulation into liposomes significantly slowed down release from the hydrogel and the release rate could be controlled by adjusting liposome characteristics, such as size and composition.
520 $a Then, the potential of the liposome/thermosensitive solution formulation for the sustained delivery of therapeutic peptides was evaluated using hexareline, a small molecular weight peptide, as model drug. Hexareline is a growth hormone secretagogue. The in vivo studies revealed that the subcutaneous administration of the new system could not provide detectable plasmatic concentrations of hexareline beyond 24 hours.
520 $a A local application using the thermosensitive solution was hence tested. We proposed to use the formulation for the delivery of antineoplastic agents at tumor resection sites in order to prevent the growth of residual cancer cells. The in vitro release studies showed that the hydrogel could sustain the release of paclitaxel, an antineoplastic agent used in breast and ovarian cancer, over at least 1 month. (Abstract shortened by UMI.)
590 $a School code: 0992.
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0572
710 2 0 $a Universite de Montreal (Canada). $3 1018132
773 0 $t Dissertation Abstracts International $g 66-04B.
790 $a 0992
791 $a Ph.D.
792 $a 2005
793 $a French and English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=NR01147